title: Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough.
abstract: BACKGROUND
  Dry cough is a common side-effect of the angiotensin converting enzyme inhibitors (ACEI) and is a major limiting factor of their use. It has been suggested that ACEI cause this side-effect by potentiation of the bradykinin effect. Previous work in our laboratory has shown that noscapine, an antitussive drug, inhibits the effect of bradykinin.
  
  
  METHODS
  To investigate the effect of noscapine on ACEI-induced cough, 611 hypertensive patients who were being treated with ACEI were evaluated for the incidence of persistent dry cough.
  
  
  RESULTS
  A cough had developed in 65 (10.6%) patients, two (3.1%) of whom also had severe respiratory distress that required hospitalisation and immediate discontinuation of the ACEI. Forty-two (64.6%) patients had developed a mild cough and 21 (32.3%) patients had developed a moderate to severe cough. The patients with moderate to severe cough received 15 mg of noscapine, orally three times daily, while they continued ACEI. Noscapine effectively resolved the cough in 19 (90%) patients within 4-9 days of starting treatment.
  
  
  CONCLUSIONS
  Noscapine, possibly by inhibition of bradykinin synthesis, eliminates ACEI-induced cough in the majority of patients and allows them to continue with ACEI therapy.
authors.affiliation: Division of Nephrology, Rasool Akram Medical Center, Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Mooraki
authors.forename: Aria
authors.initials: A
authors.lastname: Jenabi
authors.forename: Mosadegh
authors.initials: M
authors.lastname: Jabbari
authors.forename: Mohammad I
authors.initials: MI
authors.lastname: Zolfaghari
authors.forename: Sahar Z
authors.initials: SZ
authors.lastname: Javanmardi
authors.forename: Masoud
authors.initials: M
authors.lastname: Mahmoudian
authors.forename: Bahar
authors.initials: B
authors.lastname: Bastani
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000996:Antitussive Agents / Q000627:therapeutic use*; D001920:Bradykinin / Q000502:physiology; D003371:Cough / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009665:Noscapine / Q000627:therapeutic use*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000996:Antitussive Agents; D009665:Noscapine; D001920:Bradykinin